liveBook · Manning

PandaOmics

As explained in Build AI Drug Discovery Pipelines

PandaOmics is a computational drug-discovery platform that analyzes omics data and scientific literature to support biological target identification.

PandaOmics is a computational drug-discovery platform for identifying biological targets by combining omics measurements, genetic associations, and scientific-literature evidence. section 13.3.1

A typical target-discovery workflow combines:

  • Differential expression analysis compares patient and control samples. section 13.3.1
  • Pathway enrichment highlights biological processes associated with dysregulated genes. section 13.3.1
  • Network analysis prioritizes hub genes, while literature mining adds reported gene–disease relationships. section 13.3.1
  • Novelty scoring balances biological rationale against prior investment and patent coverage. section 13.3.1

Rentosertib target discovery

For idiopathic pulmonary fibrosis, PandaOmics integrated patient lung transcriptomics, bronchoalveolar lavage proteomics, pulmonary-fibrosis GWAS data, and literature mined from more than 30 million publications. TNIK emerged as a promising target because evidence was substantial while publications and selective inhibitors were scarce. section 13.3.1

Figure 13.7 The four stages of the rentosertib program. Multi-omics data and literature flow through PandaOmics to a scored target list; Chemistry42 generates and optimizes candidates against a multi-objective reward; experimental readouts feed back to refine the models; clinical development follows. Sections 13.3.1 through 13.3.4 walk through each stage.

The systems-flow diagram shows how PandaOmics produces a scored target list before molecule generation, experimental feedback, and clinical development. section 13.3.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Combines several evidence streams and prioritization analyses but does not detail platform implementation.
Examples
Uses idiopathic pulmonary fibrosis, rentosertib, and TNIK as a target-discovery case.
What you can do after
Evaluate and prioritize disease targets using integrated biological, genetic, and literature evidence.
How it connects
Connects transcriptomics, proteomics, GWAS, differential expression, pathway enrichment, network analysis, and literature mining.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.